April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Evaluation of Transepithelial Corneal Collagen Cross-Linking (CXL) at 6 months and 1 year Follow Up in Patients with Different Proprietary Transepithelial Riboflavin Solutions
Author Affiliations & Notes
  • Jennifer Loh
    South Florida Eye Associates, Boca Raton, FL
  • William Trattler
    Center for Excellence in Eye Care, Miami, FL
  • Roy Rubinfeld
    Washington Eye Physicians and Surgeons, Chevy Chase, MD
  • Gabriela Perez
    Center for Excellence in Eye Care, Miami, FL
  • Eduardo J Polania
    Center for Excellence in Eye Care, Miami, FL
  • Rosane Correa
    Center for Excellence in Eye Care, Miami, FL
  • Footnotes
    Commercial Relationships Jennifer Loh, None; William Trattler, CXLO (C); Roy Rubinfeld, CXLO (C); Gabriela Perez, None; Eduardo Polania, None; Rosane Correa, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 4220. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jennifer Loh, William Trattler, Roy Rubinfeld, Gabriela Perez, Eduardo J Polania, Rosane Correa; Evaluation of Transepithelial Corneal Collagen Cross-Linking (CXL) at 6 months and 1 year Follow Up in Patients with Different Proprietary Transepithelial Riboflavin Solutions. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4220.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Transepithelium corneal cross linking has been reported to be ineffective. The purpose of this analysis was to demonstrate efficacy and compare operative procedure time relative to standard crosslinking in a clinical setting.

Methods: Patients with a diagnosis of keratoconus or post-Lasik ectasia who had undergone Transepithelial CXL in one or both eyes were included in this analysis. Patients with previous RK, INTACS, repeat CXL procedures, and/or patients who were pseudo-phakic or had a diagnosis of cataract were excluded from this analysis. Outcome measures included intraoperative transepithelial corneal stromal riboflavin loading times, and UCVA, BSCVA, and K Max at 6 months and 1 year follow up visits. Corneal stromal loading was assessed by slit lamp examination.

Results: 199 eyes were treated with proprietary riboflavin formulation 1. Loading time ranged from 30 to 100 minutes (average 56.3 minutes). 70% of these eyes were male and the average age was 35.7 years old. 84% of eyes had a pre-Op diagnosis of keratoconus. 127 eyes were treated with proprietary riboflavin formulation 2. Loading time ranged from 8 to 60 minutes (average 22.17 minutes). 70% of these eyes were male and the average age was 36 years old. 88% of eyes had a pre-Op diagnosis of keratoconus. At 6 months post-CXL, 52% and 52% of eyes (formulation 1) and 45% and 47% of eyes (formulation 2) improved 1 or more lines in UCVA and BSCVA from pre-Op. Patients treated with formulation 1 and formulation 2 experienced 0.24D flattening and 1.36D in K Max, respectively, at 6 months follow-up. At 1 year follow up, 59% and 55% of eyes (formulation 1) and 63% and 50% of eyes (formulation 2) experienced 1 or more lines of improvement in UCVA and BSCVA. Patients treated with formulation 1 and formulation 2 experienced 0.52D flattening and 2.00D flattening, respectively, in K max from Pre-Op.

Conclusions: The efficacy of trans-epithelium corneal cross linking depends on the formulation and the application of the solution. The presented results demonstrate that trans- epithelium cross linking with an appropriate formulation can provide an efficacy that is comparable to the epi-off Dresden protocol without substantial increase in the loading time.

Keywords: 574 keratoconus  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×